Therapure Biopharma to divest CDMO business for $290m

A joint venture (JV) between 3SBio and CPE Funds has entered an asset purchase agreement to purchase Canadian biologics manufacturer Therapure Biopharma ’s contract development and manufacturing (CDMO) business, Therapure Biomanufacturing, for $290m.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news